Home > News > Arrowhead Research Units to Combine
January 19th, 2008
Arrowhead Research Units to Combine
Abstract:
Nanotechnology developer Arrowhead Research Corp. said Friday its subsidiary Calando Pharmaceuticals Inc. will become part of another of its subsidiaries, Insert Therapeutics Inc.
Arrowhead said as part of the deal, the subsidiaries will be recapitalized to eliminate their preferred stock.
At Insert, each preferred share will be converted into one common share, the company said. At Calando, each preferred share will be converted into one Calando common share.
The company said shareholders of Calando stock will receive Insert shares at an exchange ratio of about 5.97 shares of Insert stock for each Calando share. Outstanding options to buy Calando stock will be converted into an option to buy about 5.97 shares of Insert stock.
Source:
money.cnn.com
Related News Press |
News and information
Researchers develop artificial building blocks of life March 8th, 2024
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Acquisitions/Mergers/Splits
180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020
180 Degree Capital Corp.’s Portfolio Company, Synacor, Inc., Agrees to Merge with Qumu Corporation in All-Stock Transaction February 11th, 2020
Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||